Clomiphene

ID: clomiphene

Aliases: clomifene, clomiphene citrate, Clomid

Type: compound

Route/form: oral

Status: approved_or_off_label_context_dependent

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, human_trial, label, meta_analysis

Linked sources: 7

Broad outcomes: Hormones / fertility / sexual health, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• estrogen receptor antagonist in hypothalamic-pituitary axis
• LH/FSH upregulation
• mixed enclomiphene and zuclomiphene isomers

Optimization domains

• SERM
• fertility
• testosterone
• endocrine
• PCT discussions

Research basis

• Optimization angle: upstream LH/FSH stimulation is the reason clomiphene is discussed for endogenous testosterone support, fertility preservation, or PCT-style recovery.
• Human male hypogonadism and infertility meta-analyses support testosterone/gonadotropin effects in selected men, and AAS-fertility cohorts explain why it appears alongside hCG in recovery protocols.
• Racemic clomiphene is a useful comparator to enclomiphene because it shares the SERM mechanism but has a different isomer mixture and persistence profile.

Limits, risks, and missing evidence

• Racemic clomiphene is not identical to enclomiphene; zuclomiphene persistence and estrogenic effects complicate extrapolation.
• Male fertility and testosterone studies do not prove robust recovery after every androgen/SARM cycle, and older antiestrogen fertility data are mixed.
• Visual symptoms, mood effects, estradiol changes, and rare thrombotic concerns matter, especially when stacked with SARMs or AAS.

Risk flags

• prescription only
• off label male context
• visual symptoms
• mood effects
• thrombotic risk

Linked papers, labels, and reviews

1. DailyMed label: clomiphene citrate tablets
   label / dailymed_clomiphene_label
   Approved ovulation-induction label; male endocrine use is off-label.
2. Clomiphene citrate and hCG are both effective in restoring testosterone in hypogonadism
   human_rct / pubmed_clomiphene_male_hypogonadism_rct_2018
   Short-course randomized male hypogonadism study.
3. Effects of clomiphene citrate on male obesity-associated hypogonadism
   human_rct / pubmed_clomiphene_obesity_hypogonadism_2018
   Randomized, double-blind, placebo-controlled male obesity-associated hypogonadism study.
4. Clomiphene citrate for male infertility: A systematic review and meta-analysis
   meta_analysis / pubmed_clomiphene_male_infertility_meta_2023
   Male infertility meta-analysis; anchors fertility-oriented clomiphene claims and endpoint limitations.
5. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis
   meta_analysis / pubmed_clomiphene_hypogonadism_meta_2022
   Male hypogonadism systematic review/meta-analysis; supports testosterone/gonadotropin effects while preserving distinction from exogenous TRT.
6. Fertility outcomes in men with prior history of anabolic steroid use
   human_trial / pubmed_aas_prior_use_fertility_hcg_clomiphene_2023
   Human fertility-recovery cohort using discontinuation plus clomiphene/hCG regimen; relevant to AAS-induced suppression discussions, not proof of safe cycling.
7. Effectiveness of antiestrogens in infertile men
   human_trial / pubmed_antiestrogens_infertile_men_1993
   Older male infertility antiestrogen follow-up; useful negative/mixed endpoint context for clomiphene/tamoxifen fertility claims.